fda tirzepatide shortage update today facing blowback after ending of Mounjaro and Zepbound Eli Lilly's Weight-Loss Drug Zepbound

CagriSema vs Comparators Feature Receptor targets CagriSema Amylin/calcitonin + GLP-1 Tirzepatide (Zepbound) GIP + GLP-1 Semaglutide alone (Wegovy) GLP-1 Cagrilintide alone Amylin/calcitonin (DACRA) Feature Dosing frequency CagriSema Once weekly Tirzepatide (Zepbound) Once weekly Semaglutide alone (Wegovy) Once weekly Cagrilintide alone Once weekly Feature Maintenance dose CagriSema 2.4 mg + 2.4 mg Tirzepatide (Zepbound) Up to 15 mg Semaglutide alone (Wegovy) 2.4 mg Cagrilintide alone 2.4 mg (in REDEFINE arms) Feature Headline weight loss CagriSema 20.4% at 68 wks (REDEFINE 1, treatment-policy) Tirzepatide (Zepbound) Up to 22.5% at 72 wks (SURMOUNT-1, 15 mg arm) Semaglutide alone (Wegovy) 14.9% at 68 wks (REDEFINE 1 reference arm) Cagrilintide alone 11.5% at 68 wks (REDEFINE 1 reference arm) Feature FDA status (June 2026) CagriSema NDA filed Dec 2025

Ros PA process runs 2 to 3 weeks typically, 6 to 10 weeks after a denial and appeal

A general guideline is to exhale during the most challenging part of the movement (e.g., pushing the weight up in a press, standing up from a squat) and inhale during the easier phase

Competition in the obesity drug sector is intensifying rapidly

Future Directions in GHK-Cu Oral Delivery Researchers are actively exploring ways to improve the oral bioavailability of peptides like GHK-Cu: Advanced formulations such as enteric coatings that resist stomach acid

Understanding IV Glutathione Treatment Facial skin brightening drips medically known as intravenous (IV) glutathione therapy involve administering a powerful antioxidant called glutathione directly into your bloodstream through an IV drip